Search research articles
Contact Us
Filters
Showing results (401-410 of 24,158) with videos related to
Page
of 2,416
Sort By:
ACS Medicinal Chemistry Letters
|
September 17, 2025
Novel Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness, and CNS Disorders
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
September 17, 2025
Novel Fused Heterocycles as 5‑HT2A Receptor Agonists for Treating Neurological Diseases, Namely, Depression, Anxiety, Substance Abuse, and Headaches
Ram W Sabnis
Journal of Education and Health Promotion
|
September 22, 2025
MODY: Strategies for a unique form of diabetes
Ram K Garg
ACS Medicinal Chemistry Letters
|
September 17, 2025
Novel Compounds as 5‑HT2A Agonists for Treating Mental Illness or CNS Disorders
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
August 20, 2025
Novel Spiropiperidine Urea-Derived Compounds as Soluble Epoxide Hydrolase Inhibitors for Treating Diabetic Retinopathy
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
August 20, 2025
Novel 5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinoline-5-yl Amine Compounds as 5‑HT2C Agonists for Treating Psychotic Disorders, Namely, Personality Disorders and Eating Disorders
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
July 16, 2025
Novel Phenoxy and Benzyloxy Substituted Psychedelic Psychoplastogens as 5‑HT2C Agonists for Treating Neurological Diseases
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
July 16, 2025
Novel Indazole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
July 16, 2025
Novel Pyrrolidinyl Derivatives as HCN2 Modulators for Treating Central Nervous System and Psychiatric Disorders, Namely, Autism, Mood Disorders and Schizophrenia
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
December 17, 2025
Novel Imidazopyridazine Compounds as IL-17 Inhibitors for Treating Inflammatory Diseases
Ram W Sabnis
Page
of 2,416
Search research articles
Search
Showing results (401-410 of 24,158) with videos related to
Sort By:
Page
of 2,416
ACS Medicinal Chemistry Letters
|
September 17, 2025
Novel Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness, and CNS Disorders
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
September 17, 2025
Novel Fused Heterocycles as 5‑HT2A Receptor Agonists for Treating Neurological Diseases, Namely, Depression, Anxiety, Substance Abuse, and Headaches
Ram W Sabnis
Journal of Education and Health Promotion
|
September 22, 2025
MODY: Strategies for a unique form of diabetes
Ram K Garg
ACS Medicinal Chemistry Letters
|
September 17, 2025
Novel Compounds as 5‑HT2A Agonists for Treating Mental Illness or CNS Disorders
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
August 20, 2025
Novel Spiropiperidine Urea-Derived Compounds as Soluble Epoxide Hydrolase Inhibitors for Treating Diabetic Retinopathy
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
August 20, 2025
Novel 5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinoline-5-yl Amine Compounds as 5‑HT2C Agonists for Treating Psychotic Disorders, Namely, Personality Disorders and Eating Disorders
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
July 16, 2025
Novel Phenoxy and Benzyloxy Substituted Psychedelic Psychoplastogens as 5‑HT2C Agonists for Treating Neurological Diseases
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
July 16, 2025
Novel Indazole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
July 16, 2025
Novel Pyrrolidinyl Derivatives as HCN2 Modulators for Treating Central Nervous System and Psychiatric Disorders, Namely, Autism, Mood Disorders and Schizophrenia
Ram W Sabnis
ACS Medicinal Chemistry Letters
|
December 17, 2025
Novel Imidazopyridazine Compounds as IL-17 Inhibitors for Treating Inflammatory Diseases
Ram W Sabnis
Page
of 2,416